Myeloma UK was established in 1997 to change the lives of patients with myeloma and related conditions and realise our ambition of making myeloma history.
Myeloma is a very individual blood cancer, and every patient’s experience is different.
When we first started our work
The average length of time a patient with myeloma could expect to survive was between 12 and 24 months.
Today, that time has quadrupled to between four to eight years, with three out of ten patients living for ten years or more after their diagnosis – and some for much longer still.
There were no bespoke myeloma treatments available to patients via the NHS.
Today, we have eight myeloma drugs in active use in the NHS pathway that can be delivered in 12 different combinations throughout a patient’s treatment journey.